First it was Boehringer. Now drugmaker AstraZeneca has followed suit by capping out-of-pocket costs for inhalers to $35/mo. That’s down from over $600. But this doesn’t happen by itself.
It took pressure by lawmakers like Sen. Bernie Sanders and from engaged consumer activists.
